Company Profile (AI Text)
Name: Quadrant Biosciences
Canonical URL: https://wefunder.com/quadrant.biosciences
Updated at: 2026-06-15T05:00:18Z

Tagline: We develop novel, saliva based tests for Autism, COVID-19 and Parkinson's. 
Elevator pitch: We develop epigenetic saliva biomarkers including the world's first saliva test for autism. We recently received FDA emergency use authorization for a COVID-19 saliva test, and are currently working on developing tests for Parkinson's disease, concussion, and Anorexia nervosa.

Key claims:
- Total raised on Wefunder: 1339935 | citation: https://wefunder.com/quadrant.biosciences#claim-total-raised
- Total investors: 1299 | citation: https://wefunder.com/quadrant.biosciences#claim-total-investors

Verified facts:
- Total raised on Wefunder: 1339935 | observed_at: 2026-06-15T05:00:18Z | expires_at: 2026-06-16T05:00:18Z
- Total investors: 1299 | observed_at: 2026-06-15T05:00:18Z | expires_at: 2026-06-16T05:00:18Z

Computed metrics:
- total_amount_raised: 1339935
- total_investors: 1299
- team_size: 10
- featured_investor_count: 0
- faq_count: 5
- recent_post_count: 10

Quick facts:
- Applied our expertise in RNA analysis to co-develop FDA authorized COVID-19 saliva test with SUNY. | citation: https://wefunder.com/quadrant.biosciences#claim-fact-1
- Developed & commercialized world's first saliva based epigenetic test for autism spectrum disorder. | citation: https://wefunder.com/quadrant.biosciences#claim-fact-2
- Sales from our new saliva COVID-19 tests have exceeded $6.5MM to date since September 2020. | citation: https://wefunder.com/quadrant.biosciences#claim-fact-3
- We are working with NY State to test municipalities' wastewater for COVID-19. | citation: https://wefunder.com/quadrant.biosciences#claim-fact-4
- Working with SUNY on pooled saliva surveillance of returning college students for COVID-19. | citation: https://wefunder.com/quadrant.biosciences#claim-fact-5
- Development of Parkinson's disease, concussion, and Anorexia Nervosa, diagnostic tools in progress. | citation: https://wefunder.com/quadrant.biosciences#claim-fact-6
- Our company is led by a former Chairman & CEO of Morgan Stanley Bank, Richard Uhlig. | citation: https://wefunder.com/quadrant.biosciences#claim-fact-7

FAQ:
- Q: Is this fund raising under Regulation A or Title III?
  A: Hello Ram, Quadrant Biosciences is offering this as a Reg A. Thanks, The Quadrant Team
- Q: Hi, Your max raise goal is $15M and you stated "Quadrant Biosciences Inc is not conducting a Regulation Crowdfunding offering." So this is a Reg D offering? Please clarify. Thanks.
  A: Hello Helen, The Quadrant Team, along with the fine people at Wefunder, has spent countless hours reviewing these pages to make sure nothing has slipped through. That being said, the above stated quote, "Quadrant Biosciences Inc is not conducting a Regulation Crowdfunding offering" has been removed from the webpage. We are conducting a Reg A offering. Thank you for pointing this out to us and please accept our apologies. We hope to see you as an investor, The Quadrant Team
- Q: What valuation was given to the company in the latest funding round in Dec19?
  A: Hello William, The valuation of the company following our last Regulation D common stock offering (December 2019) was approximately $222 Million. Please note that the shares purchased in the Regulation D offering in December are subject to 1 year holding period which is a significant liquidity restriction whereas the shares purchased through this Regulation A offering are freely transferable. We hope this explanation is helpful and that you choose to join us as an investor! Thanks, The Quadra...
- Q: What's the science behind testing for autism and other disease states that are primarily diagnosed through behavioral patterns?
  A: Thank you for asking! This is game-changing technology which has been developed over the past 5 years by SUNY Upstate Medical University, the Penn State College of Medicine and Quadrant Biosciences. A quick video about our science is available here: https://vimeo.com/367101683 . Further, we’ve made a commitment to transparency in our work – our 7 peer-reviewed publications related to Autism Spectrum Disorder are available here: https://www.clarifiasd.com/our-science/ (but if you only have tim...
- Q: Hello ,is there any plan for future exit ( acquisition or going Public)?
  A: This is a very savvy question – thank you. As you can likely intuit, this offering presages our intended public listing. As you may know, many of the requirements to offer securities in this Regulation A offering conform to the high standards of a public offering (i.e. financial statements audited by a PCAOB certified accounting firm); this offering will help us achieve other listing requirements as well (i.e. to list on NASDAQ, companies must also have at least 450 round lot shareholders or ...

Recent posts:
- One Day Left to Invest! (2021-02-17T15:43:08Z) https://wefunder.com/feed/142054
- Offering Closing Soon (2021-02-16T15:34:09Z) https://wefunder.com/feed/142014
- One Week Left to Invest (2021-02-11T23:23:51Z) https://wefunder.com/feed/141921
- Quadrant Concussion Research in the News (2021-02-10T22:22:34Z) https://wefunder.com/feed/141877
- Offering Closing Soon! A Note from CEO Rich Uhlig (2021-02-05T21:36:23Z) https://wefunder.com/feed/141736
- Investment Closing Soon! (2021-02-02T20:16:58Z) https://wefunder.com/feed/141650
- Quadrant Partners with SUNY Upstate to Build New COVID-19 Lab in Buffalo! (2021-02-01T19:36:42Z) https://wefunder.com/feed/141600
- Quadrant and SUNY Upstate Project of the Year Award Update (2021-01-28T17:03:59Z) https://wefunder.com/feed/141502
- An Interview with Rich Uhlig: "RNA breakthroughs in autism, concussions, and COVID-19" (2021-01-12T17:32:52Z) https://wefunder.com/feed/140904
- MedTech salutes the Clarifi COVID-19 Saliva Swab as Project of theYear! (2021-01-01T18:07:27Z) https://wefunder.com/feed/140645